A Randomized Trial of Low-Dose Aspirin in the Prevention of Clinical Type 2 Diabetes in Women

DSpace/Manakin Repository

A Randomized Trial of Low-Dose Aspirin in the Prevention of Clinical Type 2 Diabetes in Women

Show simple item record

dc.contributor.author Pradhan, Aruna Das
dc.contributor.author Cook, Nancy Romanowicz
dc.contributor.author Manson, JoAnn Elisabeth
dc.contributor.author Ridker, Paul M.
dc.contributor.author Buring, Julie Elizabeth
dc.date.accessioned 2011-04-22T17:59:00Z
dc.date.issued 2009
dc.identifier.citation Pradhan, Aruna D., Nancy R. Cook, JoAnn E. Manson, Paul M. Ridker, and Julie E. Buring. 2009. A Randomized Trial of Low-Dose Aspirin in the Prevention of Clinical Type 2 Diabetes in Women. Diabetes Care 32(1): 3-8. en_US
dc.identifier.issn 0149-5992 en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:4874327
dc.description.abstract OBJECTIVE—Subclinical inflammation is linked with the development of type 2 diabetes, and epidemiologic data suggest that this association may be stronger in women. Although small clinical studies have shown a prominent hypoglycemic effect of short-term high-dose aspirin, no randomized trials have directly evaluated the efficacy of aspirin in diabetes prevention at doses acceptable for use in routine clinical practice. We evaluated whether chronic low-dose aspirin prevents the development of clinical diabetes among initially healthy American women. RESEARCH DESIGN AND METHODS—Subjects were enrolled in the Women's Health Study, a 10-year randomized double-blind, placebo-controlled trial of aspirin and vitamin E for primary prevention of cardiovascular disease and cancer. Between 1992 and 1995, 38,716 women aged ≥45 years and free of clinical diabetes were randomly assigned to either low-dose aspirin or placebo (median follow-up 10.2 years). Documented clinical type 2 diabetes was prospectively evaluated throughout the trial. RESULTS—Among women randomly assigned to receive aspirin (n = 19,326) or placebo (n = 19,390), there was no statistically significant difference in the incidence of type 2 diabetes. There were 849 cases of diabetes in the aspirin group and 847 in the placebo group (rate ratio 1.01 [95% CI 0.91–1.11]). Stratification by diabetes risk factors including age, BMI, family history of diabetes, physical activity, A1C, and high-sensitivity C-reactive protein did not support a modulating effect of these variables. Analyses accounting for treatment duration and adherence similarly found no beneficial effects. CONCLUSIONS—These data suggest that long-term low-dose aspirin does not prevent the development of clinical type 2 diabetes in initially healthy women. en_US
dc.language.iso en_US en_US
dc.publisher American Diabetes Association en_US
dc.relation.isversionof doi:10.2337/dc08-1206 en_US
dc.relation.hasversion http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606820/pdf/ en_US
dash.license LAA
dc.title A Randomized Trial of Low-Dose Aspirin in the Prevention of Clinical Type 2 Diabetes in Women en_US
dc.type Journal Article en_US
dc.description.version Version of Record en_US
dc.relation.journal Diabetes Care en_US
dash.depositing.author Cook, Nancy Romanowicz
dc.date.available 2011-04-22T17:59:00Z
dash.affiliation.other SPH^Epidemiology en_US
dash.affiliation.other HMS^Medicine-Brigham and Women's Hospital en_US
dash.affiliation.other SPH^Epidemiology en_US
dash.affiliation.other HMS^Medicine-Brigham and Women's Hospital en_US
dash.affiliation.other SPH^Epidemiology en_US
dash.affiliation.other HMS^Medicine-Brigham and Women's Hospital en_US
dash.affiliation.other SPH^Epidemiology en_US
dash.affiliation.other HMS^Population Medicine en_US
dash.affiliation.other HMS^Medicine-Brigham and Women's Hospital en_US
dash.affiliation.other SPH^Biostatistics en_US

Files in this item

Files Size Format View
2606820.pdf 109.3Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters